KEYNOTE-B21 / ENGOT-en11 / GOG-3053)

A Phase 3, Randomized, Double-Blind Study of Pembrolizumab versus

Placebo in Combination With Adjuvant Chemotherapy With or Without Radiotherapy for the Treatment of Newly Diagnosed High-Risk Endometrial Cancer After Surgery With Curative Intent.